JP2008510754A5 - - Google Patents

Download PDF

Info

Publication number
JP2008510754A5
JP2008510754A5 JP2007528715A JP2007528715A JP2008510754A5 JP 2008510754 A5 JP2008510754 A5 JP 2008510754A5 JP 2007528715 A JP2007528715 A JP 2007528715A JP 2007528715 A JP2007528715 A JP 2007528715A JP 2008510754 A5 JP2008510754 A5 JP 2008510754A5
Authority
JP
Japan
Prior art keywords
salt
lercanidipine
acid
acid addition
addition salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2007528715A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008510754A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2005/009043 external-priority patent/WO2006021397A1/en
Publication of JP2008510754A publication Critical patent/JP2008510754A/ja
Publication of JP2008510754A5 publication Critical patent/JP2008510754A5/ja
Abandoned legal-status Critical Current

Links

JP2007528715A 2004-08-24 2005-08-22 レルカニジピンの塩 Abandoned JP2008510754A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60414904P 2004-08-24 2004-08-24
PCT/EP2005/009043 WO2006021397A1 (en) 2004-08-24 2005-08-22 Lercanidipine salts

Publications (2)

Publication Number Publication Date
JP2008510754A JP2008510754A (ja) 2008-04-10
JP2008510754A5 true JP2008510754A5 (enExample) 2008-10-09

Family

ID=35159792

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007528715A Abandoned JP2008510754A (ja) 2004-08-24 2005-08-22 レルカニジピンの塩

Country Status (19)

Country Link
US (1) US7683179B2 (enExample)
EP (1) EP1799644B1 (enExample)
JP (1) JP2008510754A (enExample)
KR (1) KR20070045351A (enExample)
CN (1) CN101048379A (enExample)
AR (1) AR050467A1 (enExample)
AU (1) AU2005276619B2 (enExample)
BR (1) BRPI0514606A (enExample)
CA (1) CA2575078A1 (enExample)
EA (1) EA011773B1 (enExample)
ES (1) ES2462921T3 (enExample)
IL (1) IL180905A0 (enExample)
MX (1) MX2007002141A (enExample)
NO (1) NO20071515L (enExample)
NZ (1) NZ553127A (enExample)
PE (1) PE20060629A1 (enExample)
TW (1) TW200613275A (enExample)
WO (1) WO2006021397A1 (enExample)
ZA (1) ZA200702364B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE05643B1 (et) * 2001-02-24 2013-04-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ksantiini derivaadid, nende valmistamine ja kasutamine ravimina
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
AR052918A1 (es) * 2005-02-25 2007-04-11 Recordati Ireland Ltd Clorhidrato de lercanidipina amorfo
AR053023A1 (es) * 2005-02-25 2007-04-18 Recordati Ireland Ltd Base libre de lercanidipina, metodos para su preparacion y composiciones farmaceuticas que las contienen
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
CN102838599A (zh) 2006-05-04 2012-12-26 贝林格尔.英格海姆国际有限公司 多晶型
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
RU2008151724A (ru) 2006-06-12 2010-07-20 Новартис АГ (CH) Способ получения солей n-гидрокси-3-[4-[[[2-(2-метил-1н-индол-3-ил)этил]амино]метил]фенил]-2е-2-пропенамида
WO2008040367A1 (en) * 2006-08-01 2008-04-10 Union Quimico-Farmaceutica S.A. Lercanidipine hydrobromide, a process for its preparation, crystalline forms and compositions thereof
US20080175872A1 (en) * 2006-09-28 2008-07-24 Osmotica Corp. Controlled Release Dosage Form Containing Lercanidipine and a Performance-enhancing Acid
ES2306595B1 (es) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
EP2049465A2 (en) * 2007-03-14 2009-04-22 Teva Pharmaceutical Industries Ltd. Processes for preparing solid states of o-desmethylvenlafaxine succinate
WO2009017813A1 (en) * 2007-08-02 2009-02-05 Teva Pharmaceutical Industries Ltd. O-desmethyl venlafaxine saccharinate
KR101343027B1 (ko) 2007-11-26 2013-12-18 테바 파마슈티컬 인더스트리즈 리미티드 O-데스메틸벤라팍신 푸마레이트의 결정형
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
MX2011001240A (es) * 2008-08-01 2011-08-12 Medicines Co Composiciones farmaceuticas y metodos para producir concentraciones de baja impureza de las mismas.
LT2320739T (lt) * 2008-08-01 2020-01-27 Chiesi Farmaceutici S.P.A. Farmacinės kompozicijos ir jų stabilizavimo būdai
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
BRPI0919288A2 (pt) 2008-09-10 2015-12-15 Boehring Ingelheim Internat Gmbh teriapia de combinação para tratamento de diabetes e condições relacionadas.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EA022310B1 (ru) 2008-12-23 2015-12-30 Бёрингер Ингельхайм Интернациональ Гмбх Солевые формы органического соединения
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
NZ599298A (en) 2009-11-27 2014-11-28 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
KR101409554B1 (ko) * 2010-03-29 2014-06-19 플리바 흐르바츠카 디.오.오. O-데스메틸벤라팍신 푸마레이트의 결정형
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
NZ603319A (en) 2010-06-24 2015-04-24 Boehringer Ingelheim Int Diabetes therapy
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CA2841552C (en) 2011-07-15 2020-06-23 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
JPWO2023219106A1 (enExample) * 2022-05-10 2023-11-16

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8403866D0 (en) 1984-02-14 1984-03-21 Recordati Chem Pharm Diphenylalkylaminoalkyl esters
US5696139A (en) 1995-05-12 1997-12-09 Recordati S.A., Chemical And Pharmaceutical Company Use of S-enantiomers of 1,4-dihydropyridine derivatives for treating heart failure
IT1275532B (it) * 1995-07-14 1997-08-07 Recordati Chem Pharm Uso di derivati 1,4-diidropiridinici per la prevenzione e la terapia della degenerazione aterosclerotica della parete arteriosa
US5912351A (en) 1995-05-12 1999-06-15 Recordati, S.A. Chemical And Pharmaceutical Company Anhydrous 1,4-Dihydropyridines and salts thereof
IT1301759B1 (it) * 1998-06-19 2000-07-07 Nicox Sa Sali nitrati di farmaci antiipertensivi
US6852737B2 (en) 2001-08-06 2005-02-08 Recordati Ireland Limited Crude and crystalline forms of lercanidipine hydrochloride
US20030069285A1 (en) 2001-08-06 2003-04-10 Recordati Ireland Limited Novel solvate and crystalline forms of lercanidipine hydrochloride
US6699892B2 (en) * 2002-06-04 2004-03-02 Yung Shin Pharmaceutical Industrial Co., Ltd. Pharmaceutically acceptable salt of amlodipine and method of preparing the same
WO2004035051A1 (en) * 2002-10-16 2004-04-29 Recordati Ireland Limited Lisinopril/lercanidipine combination therapy
US20040198789A1 (en) * 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations

Similar Documents

Publication Publication Date Title
NZ553127A (en) L-lactic, saccharin, cinnamic, salicyclic, benzenesulphonic and naphthalene-1,5-disulphonic acid addition salts of lercanidipine
JP2004534870A5 (enExample)
NZ307946A (en) (R)-(Z)-1-azabicyclo[2.2.1]heptan-3-one,O-[3-(3-methoxyphenyl)-2-propynyl]oxime maleate as a pharmaceutical agent useful for the alleviating pain and /or treating the symptoms of cognitive impairment
US6613906B1 (en) Crystal modification
CA2525700A1 (en) S-(-)-amlodipine nicotinate and process for the preparation thereof
CN112624983B (zh) 一种含烷基结构的联苯二芳基嘧啶类衍生物及其制备方法和应用
CN103459392B (zh) 一种制备培美曲塞盐的方法
WO2003080606A8 (en) Process for preparing a pharmaceutically active compound (granisetron)
ES2296964T3 (es) Compuestos a base de nitrato organico para el tratamiento de ateroesclerosis y enfermedades vasculares.
JP2005521751A (ja) アムロジピンニコチネート及びその製造方法
AU2004213104A1 (en) Indazolamides with analgesic activity
WO2006035433A3 (en) Use of purified donepezil maleate for preparing pharmaceutically pure amorphous donepezil hydrochloride
CA2570795A1 (en) Process for the preparation of crystal modifications for use in the preparation of esomeprazole sodium salt
JP2008524183A5 (enExample)
McMahon Crystal engineering of novel pharmaceutical forms
WO2005023769A1 (en) Process for the preparation of amlodipine salts
JP2006500337A5 (enExample)
TWI443100B (zh) 培美曲塞鹽的製法
KR100914691B1 (ko) 도네페질 또는 그의 제조용 중간체의 제조방법
WO2006090263A1 (en) Stable form i donepezil hydrochloride and process for its preparation and use in pharmaceutical compositions
US20100081824A1 (en) Processes For the preparation of different forms of (S)-(+)-Clopidogrel besylate
KR20130033242A (ko) 클로피도그렐의 공결정
AU2007227919B2 (en) Pharmaceutical composition containing clopidogrel camphorsulfonate or polymorphic forms thereof
WO2004096770A1 (en) Process for preparing almodipine mesylate monohydrate
DE60219837D1 (de) Kristalline form von quinapril hydrochlorid und verfahren zu dessen herstellung